摩根大通 2015年上海医药投资价值研究报告.pdf
文本预览下载声明
North America Equity Research
29 November 2010
Initiation
Overweight
ShangPharma Corp. SHP, SHP US
Price: $11.72
Rise of the Chinese CRO; Initiate at Overweight
Price Target: $16.00
We are initiating coverage on ShangPharma Corporation (SHP) with an Life Science Tools Diagnostics
Overweight rating and December 2011 price target of $16. The second-largest AC
Tycho W. Peterson
biopharmaceutical RD outsourcing partner based in China, ShangPharma has
(1-212) 622-6568
built an impressive franchise since being founded in 2002 and today provides over tycho.peterson@
200 customers with a range of services in the drug discovery and development
J.P. Morgan Securities LLC
chain, including discovery chemistry and biology, preclinical development, and
active pharm
显示全部